Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Amrutanjan Health Care Limited (AMRUTANJAN.NS)
Chennai, IN
Established in Chennai, India, in 1893, Amrutanjan Health Care Limited, formerly known as Amrutanjan Limited until its renaming in 2007, is a prominent manufacturer, supplier, and vendor of a broad array of wellness products. The company primarily operates across its OTC Products, Beverages, and Others divisions. Its core offerings include ayurvedic pain relief balms, non-alcoholic drinks, and feminine hygiene products. For pain management, Amrutanjan provides a comprehensive range of solutions such as traditional pain balms, various roll-ons, back pain lotions, body pain gels, joint muscle sprays, and diclofenac-based remedies. To address congestion, the company offers cold rubs, cough syrups, nasal inhalers, and Swas Mints. Additionally, its product line features sanitary napkins for women, corn caps, and hand sanitizers. Within its beverage segment, it manufactures juice drinks marketed under the Fruitnik and Fruitnik Electro+ brand names. Amrutanjan also extends its services by operating a pain management center. The company's global presence is marked by product exports to the Middle East, Africa, Southeast Asia, and other international markets.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.15% | +2.54% | +3.94% | -12.41% | -21.87% | -16.60% | -20.98% | -8.33% | -16.31% | +167.14% | +1,208.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+11.6% ★ Q1'26: +10.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+13.9% Q1'26: +6.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+7.4% Q1'26: -5.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+13.8% ★ Q1'26: +16.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+15.4% ★ Q1'26: +22.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.02× ★ Q1'26: 0.02× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
Mar 2031 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.67B
est: 1.68B (-0.9%)
|
1.87B
est: 1.87B (-0.3%)
|
2.22B
est: 2.21B (+0.4%)
|
2.22B
est: 2.58B (-14.0%)
|
2.52B
est: 2.47B (+1.9%)
|
2.61B
est: 2.86B (-8.9%)
|
3.32B
est: 3.18B (+4.4%)
|
4.51B
est: 1.68B (+168.0%)
|
1.87B
1.87B – 1.87B
+11.5% YoY
|
2.21B
2.21B – 2.21B
+18.1% YoY
|
2.58B
2.58B – 2.58B
+16.7% YoY
|
2.47B
2.47B – 2.47B
-4.2% YoY
|
2.86B
2.86B – 2.86B
+15.8% YoY
|
3.18B
3.18B – 3.18B
+11.0% YoY
|
| EBITDA |
280.63M
est: 329.21M (-14.8%)
|
357.95M
est: 313.92M (+14.0%)
|
373.99M
est: 455.59M (-17.9%)
|
361.73M
est: 417.18M (-13.3%)
|
385.30M
est: 484.17M (-20.4%)
|
391.53M
est: 560.48M (-30.1%)
|
861.66M
est: 622.14M (+38.5%)
|
758.79M
est: 329.21M (+130.5%)
|
366.94M
366.94M – 366.94M
+11.5% YoY
|
433.37M
433.37M – 433.37M
+18.1% YoY
|
505.56M
505.56M – 505.56M
+16.7% YoY
|
484.17M
484.17M – 484.17M
-4.2% YoY
|
560.48M
560.48M – 560.48M
+15.8% YoY
|
622.14M
622.14M – 622.14M
+11.0% YoY
|
| EBIT |
248.42M
est: 308.03M (-19.3%)
|
346.44M
est: 231.80M (+49.5%)
|
353.51M
est: 314.81M (+12.3%)
|
332.67M
est: 318.52M (+4.4%)
|
353.70M
est: 453.01M (-21.9%)
|
346.75M
est: 524.41M (-33.9%)
|
824.05M
est: 582.10M (+41.6%)
|
693.53M
est: 308.03M (+125.2%)
|
343.33M
343.33M – 343.33M
+11.5% YoY
|
405.48M
405.48M – 405.48M
+18.1% YoY
|
473.03M
473.03M – 473.03M
+16.7% YoY
|
453.01M
453.01M – 453.01M
-4.2% YoY
|
524.41M
524.41M – 524.41M
+15.8% YoY
|
582.10M
582.10M – 582.10M
+11.0% YoY
|
| Net Income |
150.74M
est: 183.91M (-18.0%)
|
205.76M
est: 169.47M (+21.4%)
|
214.09M
est: 234.40M (-8.7%)
|
199.73M
est: 248.11M (-19.5%)
|
245.14M
est: 234.51M (+4.5%)
|
250.83M
est: 289.74M (-13.4%)
|
611.90M
est: 321.26M (+90.5%)
|
508.35M
est: 183.91M (+176.4%)
|
229.70M
229.70M – 229.70M
+24.9% YoY
|
270.22M
270.22M – 270.22M
+17.6% YoY
|
256.77M
256.77M – 256.77M
-5.0% YoY
|
234.51M
234.51M – 234.51M
-8.7% YoY
|
289.74M
289.74M – 289.74M
+23.6% YoY
|
321.26M
321.26M – 321.26M
+10.9% YoY
|
| SGA |
468.24M
est: 338.68M (+38.3%)
|
307.23M
est: 906.35M (-66.1%)
|
390.23M
est: 998.06M (-60.9%)
|
469.00M
est: 742.63M (-36.8%)
|
518.19M
est: 498.09M (+4.0%)
|
539.44M
est: 576.60M (-6.4%)
|
580.30M
est: 640.02M (-9.3%)
|
1.15B
est: 338.68M (+240.2%)
|
377.49M
377.49M – 377.49M
+11.5% YoY
|
445.83M
445.83M – 445.83M
+18.1% YoY
|
520.10M
520.10M – 520.10M
+16.7% YoY
|
498.09M
498.09M – 498.09M
-4.2% YoY
|
576.60M
576.60M – 576.60M
+15.8% YoY
|
640.02M
640.02M – 640.02M
+11.0% YoY
|
| EPS |
5.10
est: 6.36 (-19.8%)
|
7.67
est: 7.94 (-3.4%)
|
7.46
est: 9.35 (-20.2%)
|
6.83
est: 8.88 (-23.1%)
|
8.39
est: 8.11 (+3.5%)
|
8.58
est: 10.02 (-14.4%)
|
20.94
est: 11.11 (+88.5%)
|
17.58
est: 6.36 (+176.4%)
|
7.94
7.94 – 7.94
+24.9% YoY
|
9.35
9.35 – 9.35
+17.6% YoY
|
8.88
8.88 – 8.88
-5.0% YoY
|
8.11
8.11 – 8.11
-8.7% YoY
|
10.02
10.02 – 10.02
+23.6% YoY
|
11.11
11.11 – 11.11
+10.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Matthews India Active ETF INDE INDE | 0.76% | 135.4K | 0.79% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sambhu Prasad Sivalenka | Executive Chairman & MD | 13M | male |
| Gagan Preet Singh | Compliance Officer & Company Secretary | — | male |
| Mani Bhagavatheeswaran | Chief Marketing Officer | — | male |
| N. Swaminathan | Chief Financial Officer | — | male |
| R. Narayanan | Chief Sales Officer | — | male |
| S. Jeyakanth | Chief Operating Officer of Supply Chain & Product Delivery | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AMRUTANJAN.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
